-
EP2938615
European procedure
Extract from the Register of European Patents
EP About this file: EP2938615
| EP2938615 - IMIDAZOPYRIDAZINE DERIVATIVES AS GABAA RECEPTOR MODULATORS [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 01.09.2017 Database last updated on 26.04.2025 | Most recent event Tooltip | 20.10.2017 | Lapse of the patent in a contracting state | published on 22.11.2017 [2017/47] | Applicant(s) | For all designated states Pfizer Limited Ramsgate Road Sandwich, Kent CT13 9NJ / GB | [2015/45] | Inventor(s) | 01 /
OMOTO, Kiyoyuki c/o Pfizer Limited Portway Building Granta Park Great Abington Cambridge CB21 6GP England / GB | 02 /
OWEN, Robert McKenzie c/o Pfizer Limited Portway Building Granta Park Great Abington Cambridge CB21 6GP England / GB | 03 /
PRYDE, David Cameron c/o Pfizer Limited Portway Building Granta Park Great Abington Cambridge CB21 6GP England / GB | 04 /
WATSON, Christine Anne Louise c/o Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ England / GB | 05 /
TAKEUCHI, Mifune c/o Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ England / GB | [2015/45] | Representative(s) | Pfizer European Patent Department 23-25 avenue du Docteur Lannelongue 75668 Paris Cedex 14 / FR | [2015/45] | Application number, filing date | 13812165.2 | 04.12.2013 | [2015/45] | WO2013IB60631 | Priority number, date | US201261737157P | 14.12.2012 Original published format: US 201261737157 P | [2015/45] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2014091368 | Date: | 19.06.2014 | Language: | EN | [2014/25] | Type: | A1 Application with search report | No.: | EP2938615 | Date: | 04.11.2015 | Language: | EN | The application published by WIPO in one of the EPO official languages on 19.06.2014 takes the place of the publication of the European patent application. | [2015/45] | Type: | B1 Patent specification | No.: | EP2938615 | Date: | 26.10.2016 | Language: | EN | [2016/43] | Search report(s) | International search report - published on: | EP | 19.06.2014 | Classification | IPC: | C07D487/04, A61K45/06, A61K31/5025, A61P29/00 | [2016/23] | CPC: |
C07D487/04 (EP,CN,US);
A61K31/5025 (EP,US);
A61K45/06 (US);
A61P25/00 (EP);
A61P25/04 (EP);
A61P25/08 (EP);
|
| Former IPC [2015/45] | C07D487/04 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2015/45] | Extension states | BA | 14.07.2015 | ME | 14.07.2015 | Title | German: | IMIDAZOPYRIDAZINDERIVATE ALS GABAA-REZEPTORMODULATOREN | [2015/45] | English: | IMIDAZOPYRIDAZINE DERIVATIVES AS GABAA RECEPTOR MODULATORS | [2015/45] | French: | DÉRIVÉS D'IMIDAZOPYRIDAZINE EN TANT QUE MODULATEURS D'UN RÉCEPTEUR GABAA | [2015/45] | Entry into regional phase | 14.07.2015 | National basic fee paid | 14.07.2015 | Designation fee(s) paid | 14.07.2015 | Examination fee paid | Examination procedure | 14.07.2015 | Examination requested [2015/45] | 08.02.2016 | Amendment by applicant (claims and/or description) | 20.05.2016 | Communication of intention to grant the patent | 05.09.2016 | Fee for grant paid | 05.09.2016 | Fee for publishing/printing paid | 05.09.2016 | Receipt of the translation of the claim(s) | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 20.05.2016 | Opposition(s) | 27.07.2017 | No opposition filed within time limit [2017/40] | Fees paid | Renewal fee | 04.01.2016 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | MC | 26.10.2016 | SM | 26.10.2016 | [2017/45] | Cited in | International search | [A]WO2005080355 (NEUROGEN CORP [US], et al) [A] 1-14* claims 1, 33 *; | [A]WO2012004714 (PFIZER LTD [GB], et al) [A] 1-14 * claims 1-18 * * page 26, line 25 - line 26 * | by applicant | WO9111172 | WO9402518 | WO9855148 | WO0001697 | WO0035298 | US6106864 | WO0238568 | WO03008418 | WO2008118758 | WO2010079443 | - MIRZA, N.R.; MUNRO, G., DRUG NEWS AND PERSPECTIVES, (2010), vol. 23, no. 6, pages 351 - 360 | - O. ALMARSSON; M. J. ZAWOROTKO, CHEM COMMUN, (2004), vol. 17, pages 1889 - 1896 | - HALEBLIAN, J PHARM SCI, (197508), vol. 64, no. 8, pages 1269 - 1288 | - T HIGUCHI; W STELLA, Pro-drugs as Novel Delivery Systems, ACS SYMPOSIUM SERIES, vol. 14 | - LIANG; CHEN, EXPERT OPINION IN THERAPEUTIC PATENTS, (2001), vol. 11, no. 6, pages 981 - 986 | - H. LIEBERMAN; L. LACHMAN, Pharmaceutical Dosage Forms: Tablets, MARCEL DEKKER, (1980), vol. 1 | - VERMA ET AL., PHARMACEUTICAL TECHNOLOGY ON-LINE, (2001), vol. 25, no. 2, pages 1 - 14 | - FINNIN; MORGAN, J PHARM SCI, (199910), vol. 88, no. 10, pages 955 - 958 | - WOOLF; SALTER, SCIENCE, (2000), vol. 288, pages 1765 - 1768 | - LAWRENCE ET AL., ARTHRITIS RHEUM, (2008), vol. 58, pages 15 - 35 | - AZIZ ET AL., DIG DIS, (2009), vol. 27, no. 1, pages 31 - 41 | - DWORKIN, AM J MED, (2009), vol. 122, pages S1 - S2 | - GEBER ET AL., AM J MED, (2009), vol. 122, pages S3 - S12 | - HAANPAA ET AL., AM J MED, (2009), vol. 122, pages S13 - S21 | - WOOLF, J CLIN INVEST, (2010), vol. 120, pages 3742 - 3744 |